Financial Performance - Total revenue for the year ended December 31, 2023, was RMB 1,187,468,000, a decrease of 6.1% from RMB 1,264,073,000 in 2022[2] - Gross profit for the same period was RMB 901,016,000, down 12.3% from RMB 1,027,659,000 in the previous year[2] - The loss attributable to equity holders of the parent company was RMB 1,301,005,000, representing a significant increase of 307.1% compared to a loss of RMB 319,601,000 in 2022[2] - The company reported a total comprehensive loss of RMB 1,950,241,000 for the year, compared to RMB 230,630,000 in 2022[4] - The basic loss per share for the year was RMB (1.07), compared to RMB (0.27) in 2022[4] - The company reported a pre-tax loss of RMB 2,270,645,000 for 2023, compared to a loss of RMB 434,165,000 in 2022, indicating a substantial increase in losses[35] - The company reported a net foreign exchange gain of RMB 662,000 in 2023, compared to no gain in 2022[29] - The company reported a basic and diluted loss per share of RMB (1,301,005) thousand for 2023, compared to RMB (319,601) thousand for 2022, with a weighted average number of ordinary shares outstanding of 1,211,062,599 for 2023[38] - The company reported a gross profit for 2023 of RMB 901 million, down RMB 126.6 million or 12.3% from RMB 1,027.7 million in 2022, with a gross margin of 75.9%, down 5.4% from 81.3% in 2022[81] Assets and Liabilities - Non-current assets totaled RMB 4,779,059,000 as of December 31, 2023, down from RMB 6,327,083,000 in 2022[5] - Current assets amounted to RMB 2,482,936,000, a slight decrease from RMB 2,548,703,000 in the previous year[6] - Current liabilities increased to RMB 2,601,899,000 from RMB 2,249,797,000 in 2022[6] - The company's net asset value was RMB 3,889,577,000, down from RMB 5,860,907,000 in the previous year[6] - As of December 31, 2023, the group recorded a net current liability of RMB 118,963,000, compared to a net current asset of RMB 298,906,000 in 2022[12] - Total financial liabilities as of December 31, 2023, were RMB 1,795.6 million, an increase of RMB 396.9 million or 28.4% from RMB 1,398.7 million as of December 31, 2022, primarily due to increased bank borrowings[97] - The company's debt-to-equity ratio as of December 31, 2023, was 46.2%, an increase of 22.3% from 23.9% as of December 31, 2022, mainly due to the rise in bank loan balances[97] Revenue Sources - Revenue from vaccine sales and R&D services was RMB 1,187,468 thousand, with revenue recognized at a point in time[26] - Vaccine sales for the year ended December 31, 2023, amounted to RMB 15,803,000, a decrease from RMB 17,822,000 in 2022, representing a decline of approximately 11.4%[27] - Other income and gains related to government subsidies totaled RMB 51,658,000 for 2023, compared to RMB 49,637,000 in 2022, reflecting an increase of about 4.1%[29] - Bank interest income remained stable at RMB 10,707,000 in 2023, slightly up from RMB 10,694,000 in 2022[29] Research and Development - The company has 21 vaccine products in the pipeline, covering the top ten vaccine varieties globally, with 14 clinical approvals obtained[46] - Five vaccine products are in the final stages of Phase III clinical trials, with production facilities nearly completed and preparations for market launch underway[46] - The company is expected to register three products and submit clinical applications for seven products in 2024[46] - Research and development expenses for 2023 were RMB 636.4 million, an increase of RMB 136.1 million or 27.2% from RMB 500.3 million in 2022, driven by progress in various R&D pipelines[84] Production and Quality Control - The company maintains a 100% pass rate in quality audits for its recombinant hepatitis B vaccine series since approval, indicating strong product reliability[50] - The freeze-dried rabies vaccine (Vero cells) has held a leading market position, being the second-largest supplier in the rabies vaccine market, with a consistent 100% pass rate in quality audits since commercialization in 2007[51] - The production capacity of the certified factories includes 25 million doses for rabies vaccine, 45 million doses for recombinant hepatitis B vaccine, 5.3 million doses for inactivated hepatitis A vaccine, and 16 million doses for combined vaccines[69] Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2025[117] - The company has established an international business department to accelerate its global market expansion, with registration work for products already initiated in Southeast Asia, Africa, South America, and the Middle East[77] - The company is rapidly advancing the development of a 13-valent pneumonia conjugate vaccine and a quadrivalent combined meningitis vaccine, both of which are high-priority products for international certification[77] Financial Management and Governance - The company has established an audit committee in accordance with listing rules and corporate governance codes[110] - The company did not declare or pay any dividends for the year ended December 31, 2023[110] - The company plans to issue up to 242,212,519 non-listed RMB ordinary shares to enhance its competitive strength and promote healthy business development[109]

Financial Performance - For the six months ended June 30, 2023, the company reported total revenue of RMB 540.5 million, a decrease of 8.6% compared to RMB 591.6 million in the same period of 2022[6]. - The company's main business revenue for the first half of 2023 was RMB 540.5 million, a decrease of RMB 51.1 million or 8.6% compared to RMB 591.6 million in the same period of 2022[28]. - The company's gross profit for the first half of 2023 was RMB 432.6 million, down RMB 49.0 million or 10.2% from RMB 481.6 million in the first half of 2022[30]. - The gross margin for the first half of 2023 was 80.1%, a decline of 1.3% from 81.4% in the first half of 2022[30]. - The company reported a loss before tax of RMB 309,879 thousand, compared to a loss of RMB 132,310 thousand in the previous year, indicating a significant increase in losses[85]. - The net loss attributable to equity holders of the parent for the period was RMB 250,369 thousand, compared to a profit of RMB 44,877 thousand in the same period last year[85]. - The company's loss for the first half of 2023 was RMB 257.4 million, an increase in loss of RMB 308.3 million or 605.3% compared to a profit of RMB 50.9 million in the first half of 2022, mainly due to significantly increased R&D expenses and a decrease in tax credit[40]. - The company incurred a pre-tax loss of RMB 309,879,000 for the six months ended June 30, 2023, compared to RMB 132,310,000 in the prior year[89]. - The company reported a net loss of RMB 250,369,000 for the six months ended June 30, 2023, compared to a loss of RMB 44,877,000 for the same period in 2022[88]. Revenue Breakdown - The sales breakdown for key products includes: Vero cell rabies vaccine at RMB 324.1 million (60.0%), hepatitis B vaccine at RMB 180.1 million (33.3%), and inactivated hepatitis A vaccine at RMB 21.5 million (4.0%) for 2023[6]. - The recombinant hepatitis B vaccine has generated 33.3% of the company's revenue for the six months ending June 30, 2023[8]. - The human rabies vaccine (Vero cells) accounted for 60.0% of the company's revenue for the six months ending June 30, 2023[10]. - The sales revenue of the MPSV4 vaccine reached RMB 14.7 million for the six months ending June 30, 2023[11]. - Revenue from vaccine sales was RMB 540,470,000, with all revenue recognized at a point in time[100]. Research and Development - The company has 23 vaccine candidates in the pipeline targeting 14 disease areas, with nine products having obtained 14 clinical approvals[7]. - The company has developed a robust pipeline of vaccines utilizing its proprietary mRNA technology platform, responding rapidly to emerging COVID-19 variants[16]. - The company’s R&D pipeline aligns with national policies, covering all encouraged vaccine technologies, with significant progress expected in 2023[26]. - The company’s internal R&D team is responsible for all stages of vaccine development, including preclinical research and clinical trials[20]. - The company has initiated Phase III clinical trials for the 23-valent pneumococcal polysaccharide vaccine (PPSV23) as of August 2023[20]. Clinical Trials and Approvals - The overseas Phase III clinical trial for the bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine is nearing completion, while the bivalent EV71-CA16 hand-foot-mouth disease vaccine has entered clinical trials[7]. - The company has initiated Phase III clinical trials for the lyophilized rabies vaccine in July 2023 and plans to start Phase III trials for the quadrivalent meningococcal conjugate vaccine in 2024[7]. - The bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine is in the final stages of a Phase III clinical trial in Pakistan, with plans for domestic registration based on combined clinical data expected in 2023[14]. - The 13-valent pneumococcal conjugate vaccine (PCV13) is expected to submit a drug registration application in Q1 2024, with approval anticipated in H2 2024[17]. - The EV71-CA16 bivalent hand, foot, and mouth disease vaccine is set to initiate Phase I clinical trials in Q4 2023, marking it as the first vaccine targeting both EV71 and CA16 strains[18]. Production and Capacity - The company operates four licensed factories and covers 31 provinces, autonomous regions, and municipalities in China[5]. - The company’s production capacity includes 25 million doses for rabies vaccine, 45 million doses for recombinant hepatitis B vaccine, and 5.3 million doses for inactivated hepatitis A vaccine[22]. - The company has completed the construction and equipment validation for its mRNA COVID-19 vaccine production workshop as of June 30, 2023[23]. - The company plans to establish new production facilities in the coming years to meet the strong demand for its existing vaccine products[23]. - The new production line for the hemorrhagic fever vaccine passed GMP inspection in June 2022, allowing for resumed production[12]. Financial Position and Liabilities - As of June 30, 2023, cash and cash equivalents totaled RMB 754.9 million, a decrease of RMB 42.9 million or approximately 5.4% from RMB 797.8 million as of December 31, 2022, primarily used for R&D expenses[41]. - Total financial liabilities as of June 30, 2023, amounted to RMB 1,687.5 million, an increase of RMB 288.8 million or 20.6% from RMB 1,398.7 million as of December 31, 2022, mainly due to increased bank borrowings[45]. - The capital debt ratio as of June 30, 2023, was 30.3%, an increase of 6.4% from 23.9% as of December 31, 2022, primarily due to an increase in bank loan balances[46]. - The company has obtained bank loans amounting to RMB 500 million for the construction of a new production facility, but has failed to meet certain loan covenants[77]. - The company’s total liabilities increased, with a significant rise in trade payables and other payables[89]. Shareholder Information - As of June 30, 2023, the total number of shares issued was 1,211,062,599, including 718,888,888 domestic shares and 492,173,711 H shares[58]. - The company has a significant shareholder, Mr. Zhou Yan, holding 29.23% of the domestic shares, equating to 17.35% of the total shares[57]. - The company has a significant concentration of ownership, with major shareholders holding over 5% of the total shares, indicating potential influence over corporate decisions[60]. - The company’s major shareholders include Zhuhai Hengqin Ruifan Technology Partnership, which holds 32.2% of the equity in Lifanda Bio[66]. - The company has established a long-term incentive mechanism to attract and retain talent through the employee stock incentive plan[69]. Market Outlook and Strategy - The Chinese vaccine market is projected to grow from RMB 303.6 billion in 2021 to RMB 431.4 billion by 2030, including COVID-19 vaccines[25]. - The company has set a future outlook with a revenue guidance of 2.5 billion RMB for the full year 2023, reflecting a 20% growth target[127]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish partnerships with local distributors by mid-2024[125]. - The company is implementing a new marketing strategy focused on digital channels, which is projected to increase customer engagement by 35%[127]. - The company has invested 150 million RMB in new technology for vaccine production, aiming to increase production capacity by 40%[126]. Compliance and Governance - The company is subject to the Securities and Futures Ordinance, requiring disclosure of substantial shareholders and their interests[60]. - The company maintains compliance with regulatory requirements regarding the disclosure of shareholdings and interests[60]. - The roles of the Chairman and CEO are currently held by the same individual, which the board believes facilitates effective execution of strategic plans[77]. - The interim financial statements were approved for publication by the board of directors on August 29, 2023[124]. - The company has not identified any incidents of employees violating written guidelines regarding insider trading during the reporting period[79].

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 540,470,000, a decrease of 8.6% compared to RMB 591,567,000 for the same period in 2022[2] - Gross profit for the same period was RMB 432,648,000, down 10.2% from RMB 481,625,000 in the previous year[2] - Loss attributable to equity holders of the parent company was RMB 250,369,000, a significant increase of 457.9% compared to a loss of RMB 44,877,000 in the prior period[2] - The company reported a pre-tax loss of RMB 309,879,000 for the six months ended June 30, 2023, compared to a pre-tax loss of RMB 132,310,000 in the same period last year[4] - The basic and diluted loss per share for the period was RMB 0.21, compared to RMB 0.04 in the same period last year[4] - The company reported a loss of RMB 257.4 million in the first half of 2023, an increase in loss of RMB 308.3 million or 605.3% compared to a profit of RMB 50.9 million in the first half of 2022, primarily due to increased R&D expenses and a decrease in income[66] Assets and Liabilities - Total non-current assets as of June 30, 2023, amounted to RMB 6,334,580,000, slightly up from RMB 6,327,083,000 at the end of 2022[5] - Current assets totaled RMB 2,548,273,000 as of June 30, 2023, compared to RMB 2,548,703,000 at the end of 2022[5] - Total liabilities increased to RMB 3,757,507,000 as of June 30, 2023, from RMB 3,014,879,000 at the end of 2022[6] - The company’s net asset value decreased to RMB 5,576,346,000 as of June 30, 2023, down from RMB 5,860,907,000 at the end of 2022[6] - Cash and cash equivalents, along with time deposits, totaled RMB 754.9 million as of June 30, 2023, a decrease of RMB 42.9 million or approximately 5.4% from RMB 797.8 million as of December 31, 2022, mainly used for R&D expenses[67] - Total financial liabilities as of June 30, 2023, amounted to RMB 1,687.5 million, an increase of RMB 288.8 million or 20.6% from RMB 1,398.7 million as of December 31, 2022, primarily due to increased bank borrowings[71] Revenue Breakdown - Customer contract revenue for the six months ended June 30, 2023, was RMB 540,470 thousand, a decrease of 8.6% from RMB 591,567 thousand in the same period of 2022[13] - Vaccine sales accounted for RMB 540,470 thousand, down from RMB 591,531 thousand in the previous year, while R&D services generated no revenue in 2023 compared to RMB 36 thousand in 2022[14] - The sales breakdown for the six months ended June 30, 2023, includes: RMB 324.1 million (60.0%) for rabies vaccine, RMB 180.1 million (33.3%) for hepatitis B vaccine, and RMB 21.5 million (4.0%) for inactivated hepatitis A vaccine[30] Research and Development - The company continues to focus on the research and development of human vaccine products, with ongoing efforts in commercialization[7] - Research and development expenses for the first half of 2023 increased to RMB 398.5 million, up RMB 204.5 million or 105.4% from RMB 194.0 million in the same period of 2022[60] - The company has a pipeline of 23 vaccines under development for 14 disease areas, with several in various stages of clinical trials[31] - The company is developing a bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine, with ongoing Phase III clinical trials in Pakistan, expected to be registered in China by the end of 2023[40] - The company is developing a rabies vaccine using mRNA technology, with a CTA accepted by the National Medical Products Administration, expected to be available by 2026[40] Production and Capacity - The production capacity of the licensed factories as of June 30, 2023, includes 25 million doses for rabies vaccine, 45 million doses for recombinant hepatitis B vaccine, 5.3 million doses for inactivated hepatitis A vaccine, and 16 million doses for various other vaccines[47] - The company has completed the construction and equipment validation of the mRNA COVID-19 vaccine production workshop and the serum-free rabies vaccine workshop by mid-2023[49] - The company is actively expanding its production facilities to meet the strong market demand for existing vaccine products[49] Corporate Governance and Compliance - The company is compliant with GMP standards, ensuring quality assurance in its production processes[88] - The company’s board of directors includes a diverse group of executive and non-executive members, ensuring robust governance[88] - The company is committed to adhering to the corporate governance code as outlined in the listing rules, ensuring transparency and accountability[86] Market Outlook - The Chinese vaccine market is projected to grow from RMB 303.6 billion in 2021 to RMB 431.4 billion by 2030, including COVID-19 vaccines[51] - The Chinese vaccine industry is expected to enter a new development phase, driven by technological innovation and increased public awareness of vaccination[52] Strategic Initiatives - The company has established several subsidiaries, including Aim Explorer and Aim Integrity, to enhance its operational capabilities[85] - The company aims to expand its market presence through strategic partnerships and collaborations in the biotechnology sector[88] - The company has received clinical approval for a freeze-dried rabies vaccine in October 2022, with Phase III trials starting in July 2023[31]

Vaccine Portfolio and Development - AIM Vaccine has 8 commercialized vaccines and 22 vaccine products under development, covering all 31 provinces, autonomous regions, and municipalities in China, reaching over 2,000 county-level CDC centers[4] - The company is advancing 22 vaccine candidates across 14 disease areas, with key products like the bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine in Phase III trials in Pakistan[5] - The company has commercialized 8 vaccines targeting 6 disease areas, with Hepatitis B and rabies vaccines being the leading products[10] - The company has 22 vaccines in development targeting 14 disease areas, with 9 varieties having obtained 13 clinical approvals[10] - The company's product portfolio includes both EPI (Expanded Program on Immunization) and non-EPI vaccines, leveraging five validated human vaccine platform technologies[8] - The company plans to submit multiple clinical trial applications in 2023, aiming to advance several pre-clinical candidates into clinical trials[5] - Key products like the bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine and 13-valent pneumococcal conjugate vaccine are expected to launch between 2023 and 2025[5] - The bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine is currently in Phase III clinical trials overseas, with an expected emergency launch in 2023[18][19] - The monovalent Omicron BA.5 mRNA COVID-19 vaccine plans to submit a CTA in 2023, with an expected launch in 2023[18] - The EV71-CA16 bivalent hand, foot, and mouth disease vaccine is expected to start Phase I clinical trials in Q3 2023, with a projected launch in 2026[18][21] - The 13-valent pneumococcal conjugate vaccine (PCV13) is in Phase III clinical trials, with an expected NDA submission in Q1 2024 and launch in 2024[18][20] - The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is expected to enter Phase III clinical trials in Q2 2023, with a projected launch in 2024[18][23] - The ACYW135 group meningococcal polysaccharide conjugate vaccine (MCV4) started Phase I clinical trials in Q1 2023, with Phase II expected to start in Q3 2023[22] - The freeze-dried human rabies vaccine (serum-free Vero cell) is expected to start Phase III clinical trials in Q3 2023[23] - The mRNA human rabies vaccine plans to submit a CTA in 2023, with a projected launch after 2026[18] - The quadrivalent influenza vaccine (MDCK cell) plans to submit a CTA in 2024, with a projected launch after 2026[18] - The mRNA respiratory syncytial virus (RSV) vaccine plans to submit a CTA in Q2 2024, with a projected launch after 2026[18] - The company's PCV13 vaccine completed Phase III clinical trials for primary immunization in 2022[10] Production and Manufacturing - The company's four licensed factories have a combined annual production capacity of 91.3 million doses of vaccine bulk, all passing GMP inspections in 2022[4] - The company operates four licensed manufacturing facilities and covers 31 provinces, autonomous regions, and municipalities in China with its vaccine products[8] - The company's four licensed production facilities have a combined production capacity of 91.3 million doses annually, with facilities located in Ningbo, Dalian, Taizhou, and Ningbo[26] - The Ningbo Rong'an mRNA COVID-19 vaccine production workshop completed construction, equipment debugging, and validation by the end of 2022, and has produced samples for Phase III clinical trials[27] - The company plans to establish new production facilities in the coming years to meet strong market demand for its existing vaccine products[27] - The company's new bacterial vaccine industrialization project includes completed construction of pneumonia series vaccine and DTP-Hib combined vaccine workshops, currently undergoing validation[27] - The company's licensed production facilities passed all GMP inspections conducted by the National Medical Products Administration or its local agencies in 2022[25] - The company's production facilities are equipped with advanced equipment from leading international and domestic brands, ensuring stable and high-quality supply through optimized production planning and automation[26] - The company's new production line for hemorrhagic fever vaccine passed GMP inspection in June 2022[16] Financial Performance - Revenue for 2022 decreased by 19.5% to RMB 1,264.1 million, primarily due to delayed procurement and vaccination of non-COVID vaccines amid the pandemic[8] - Freeze-dried human rabies vaccine (Vero cell) remained the top-selling product, contributing 61.5% of total revenue in 2022, though sales dropped from RMB 937.4 million in 2021 to RMB 777.0 million[9] - Hepatitis B vaccine (Hansenula yeast) accounted for 34.6% of total revenue, with sales declining from RMB 523.3 million in 2021 to RMB 436.8 million in 2022[9] - The company's main business revenue in 2022 was RMB 1,264.1 million, a decrease of 19.5% compared to RMB 1,570.1 million in 2021, primarily due to the impact of the COVID-19 pandemic[32] - The company's gross profit in 2022 was RMB 1,027.7 million, a decrease of 20.6% compared to RMB 1,294.7 million in 2021, with a gross margin of 81.3%, down 1.2% from 82.5% in 2021[35] - The company's sales cost in 2022 was RMB 236.4 million, a decrease of 14.2% compared to RMB 275.4 million in 2021, mainly due to reduced sales volume[33] - The company's other income and gains in 2022 were RMB 49.6 million, a decrease of 7.4% compared to RMB 53.6 million in 2021, primarily due to reduced government subsidies and foreign exchange gains[36] - The company's operating expenses in 2022 totaled RMB 1,444.2 million, including RMB 493.2 million in sales and distribution expenses, RMB 450.8 million in administrative expenses, and RMB 500.3 million in R&D expenses[37] - R&D expenditure in 2022 increased by 62.8% to RMB 500.3 million, driven by progress in mRNA COVID-19 vaccine, serum-free rabies vaccine, and pneumonia vaccine development[38] - Sales and distribution expenses rose by 7.2% to RMB 493.2 million in 2022, primarily due to increased employee compensation, partially offset by reduced promotional activities due to COVID-19[39] - Administrative expenses decreased by 61.4% to RMB 450.8 million in 2022, mainly due to a significant reduction in employee compensation-related share-based payments[40] - Financing costs surged by 140.1% to RMB 25.7 million in 2022, primarily due to increased bank loan interest[41] - Income tax expenses decreased by 394.3% to a credit of RMB 203.5 million in 2022, driven by lower taxable income and a tax rate reduction for a subsidiary[42] - Impairment losses on financial assets increased by 241% to RMB 27.2 million in 2022, mainly due to higher bad debt provisions for receivables[43] - Net loss in 2022 decreased by 65.9% to RMB 230.6 million, primarily due to reduced employee compensation-related share-based payments[44] - Cash and cash equivalents increased by 23.4% to RMB 797.8 million as of December 31, 2022, driven by the completion of an initial public offering[45] - Inventory increased by 37.4% to RMB 504.7 million as of December 31, 2022, due to higher raw material stockpiling and lower sales of rabies vaccines[46] - Capital expenditure decreased by 25% to RMB 856.6 million in 2022, mainly due to reduced spending on vaccine industrialization projects[48] R&D and Innovation - R&D expenses increased from approximately RMB 300 million in 2021 to RMB 500 million in 2022, a significant rise in investment for vaccine development[5] - The company has five validated human vaccine platform technologies, including mRNA vaccines, genetically engineered vaccines, and combined vaccine technologies, with at least one approved product or one vaccine in clinical trial application or clinical stage under each platform[24] - The company's internal R&D team manages all stages of vaccine development, from preclinical research to clinical trials, regulatory filings, and manufacturing process development, supported by three vaccine research institutes and four production subsidiaries[24] - The company's R&D focus includes mRNA vaccines, genetically engineered vaccines, and combined vaccine technologies, with specialized teams dedicated to each platform[24] - The company's R&D activities are led by a world-class team of scientists, including Dr. Peng Yucai, who specializes in mRNA drug development, and Mr. Zhang Fan, who has over 10 years of experience in vaccine development[24] Market and Industry Overview - China's vaccine market grew from RMB 25.1 billion in 2015 to RMB 76.1 billion in 2021, and is expected to further increase to RMB 215.7 billion by 2030 (excluding COVID-19 vaccines). Including COVID-19 vaccines, the market is projected to grow from RMB 303.6 billion in 2021 to RMB 431.4 billion by 2030[29] - As of December 31, 2022, a total of 3,478.094 million doses of COVID-19 vaccines were administered in mainland China[29] - The company is the second-largest vaccine group in China and the largest private vaccine group by batch issuance volume in 2021[4] - The company is one of the first two human vaccine companies in China to receive P3 laboratory construction permits under the 14th Five-Year Plan[4] Corporate Governance and Leadership - Guan Wen, aged 56, has been serving as the Executive Director and Executive President of the company since June 2021, assisting the CEO in internal management[60] - Jia Shaojun, aged 60, has been the Executive Director since June 2021 and assumed the role of Chief Operating Officer in March 2023[60] - Zhou Jie, aged 59, has been a Non-Executive Director since June 2021 and previously served as the Chairman of the Board from December 2016 to September 2020[63] - Zhou Xin, aged 54, has been a Non-Executive Director since June 2021 and holds a 99.99% stake in Woye Biotechnology (Liaoning) Co., Ltd[63] - Zhao Jichen, aged 59, has been a Non-Executive Director since June 2021 and previously served as Executive Director and Vice President at Ping An Bank[64] - Wang Aijun, aged 50, has been a Non-Executive Director since June 2021 and is the Chairman of Meihua Biological Technology Group[64] - Ker Wei Pei, aged 66, has been an Independent Non-Executive Director since September 2020 and serves as the Audit Committee Chairman of Zhejiang Expressway[66] - Guo Xiaoguang, aged 50, was appointed as an Independent Non-Executive Director in February 2021[66] - Guo served as General Manager of Huaxi Jinzhi Investment Co., Ltd. from September 2017 to February 2021[67] - Ouyang has been an independent non-executive director of Ping An Insurance (Group) Company of China since August 2017[68] - Wen was awarded the National Science and Technology Progress Award by the State Council of China in November 2015 for her research on SARS pathogen and prevention[68] - Song has been the Chairman of the Supervisory Committee since February 2021[69] - Ma has over 25 years of experience in financial accounting, treasury, corporate finance, and tax affairs[69] - Niu has been the Chief Financial Officer since October 2015, responsible for the company's financial management[70] - Liu has served as the Chief Investment Officer since March 2022, overseeing the company's investment management and external information disclosure[70] - Liu holds a W.P. Carey Executive MBA degree, obtained in May 2018[70] - Niu holds a W.P. Carey Executive MBA degree, obtained in May 2020[70] - Liu has been a director of Livanda Biotech since May 2021[70] Legal and Regulatory Matters - The company faces legal claims totaling approximately RMB 12.539 million related to disputes with a marketing service provider, with a recorded liability of RMB 4.496 million. A first-instance judgment in July 2022 required the company to pay RMB 4.483 million, and an appeal is pending as of December 31, 2022[52] - Another legal claim involves a creditor's subrogation lawsuit, with a claimed amount of approximately RMB 80.198 million. A first-instance judgment in October 2022 required the company's subsidiary to pay RMB 28.697 million plus interest, and an appeal is ongoing as of December 31, 2022[52] Environmental, Social, and Governance (ESG) - The company has established detailed internal rules on environmental protection, including emissions of waste gas, wastewater, solid waste, and noise control, and has complied with applicable Chinese environmental laws and regulations during the reporting period[77] - The company's ESG report covers the period from January 1, 2022, to December 31, 2022, and includes all subsidiaries and research institutions[179] - The company's board has established an ESG governance framework and set group emission reduction targets and an "Energy Conservation Regulation"[180] - The company actively communicates with stakeholders, including shareholders, employees, government agencies, suppliers, customers, and the community[181] - Stakeholder engagement methods include general meetings, public disclosures, roadshows, management meetings, and community activities[182] - Total exhaust emissions in 2022 were approximately 1,166.5 kg, with an emission density of 92.3 kg per RMB 100 million in revenue[188] - Nitrogen oxides (NOx) accounted for 1,082.6 kg of emissions, with a density of 85.6 kg per RMB 100 million in revenue[189] - Total greenhouse gas emissions in 2022 were approximately 53,586.0 tons of CO2 equivalent, with an emission density of 4,239.0 tons of CO2 equivalent per RMB 100 million in revenue[190] - Direct greenhouse gas emissions totaled 148.82 tons of CO2 equivalent, with a density of 11.77 tons per RMB 100 million in revenue[191] - Indirect greenhouse gas emissions from electricity usage were 52,856.4 tons of CO2 equivalent, with a density of 4,181.3 tons per RMB 100 million in revenue[192] - The company emitted 148,557.3 tons of non-hazardous waste, primarily wastewater, with a density of 11,752.0 tons per RMB 100 million in revenue[194] - The company aims to reduce greenhouse gas emissions by 10% in 2023 compared to 2022 levels[195] - The company consumed approximately 54,000 liters of gasoline, 65.693 million kWh of electricity, and 793,000 cubic meters of water in 2022[197] - The company's energy consumption density in 2022 was 0.4 liters of gasoline per 100 million RMB revenue, 519.7 kWh of electricity per 100 million RMB revenue, and 6.3 cubic meters of water per 100 million RMB revenue[198] - The company used 66.6 tons of plastic, 109.5 tons of paper, 0.2 tons of metal, and 50.8 tons of other materials (including glass) for product packaging in 2022[199] - The company aims to reduce electricity consumption by 5% in 2023 compared to 2022[200] Shareholder and Investor Relations - The company's H股 was listed on the Hong Kong Stock Exchange on October 6, 2022, with an issue price of HK$16.16 per share, raising a net amount of approximately HK$91.61 million[74][82] - The company's largest customer accounted for 2.1% of total sales, while the top five customers combined accounted for 6.3% of total sales[80] - The largest supplier accounted for 11.5% of total purchases, and the top five suppliers combined accounted for 27.1% of total purchases[80] - The company's total issued share capital as of December 31, 2022, was 1,211,062,599 shares, with 59.36% being domestic shares and 40.64% being H shares[83] - The company did not recommend paying a final dividend for the twelve months ended December 31, 2022[78] - The company's main business is the research, development, production, and commercialization of human vaccines in China[75] - The company has no distributable reserves as of December 31, 2022 (same as December 31, 2021)[84] - The company's dividend policy emphasizes maintaining sufficient cash reserves to meet funding needs, future growth, and shareholder value[85] - The company's controlling shareholder, Mr. Zhou Yan, leased properties to the company with a total area of 1,979 square meters in Shanghai, with an annual rent of RMB 9,540,000 for the first year[88] - Mr. Zhou Yan holds 210,135,235 domestic shares, representing 29.23% of the domestic share class and 17.35% of the total shares[95] - Mr. Zhou Yan also holds 23,254,765 H-shares, representing 4.72% of the H-share class and 1.92% of the total shares[95] - Mr. Zhou Jie and Mr. Zhou Xin each hold 40,000,000 domestic shares, representing 5.56% of the domestic share class and 3.30% of the total shares[95] - Ms. Wang Aijun holds 25,000,000 domestic shares and 25,000,000 H-shares, representing 3.48% and 5.08% of the respective share classes, and 2.06% of the total shares[95] - Mr. Jia Shaojun holds 25,000,000 domestic shares and 10,310,000 H-shares, representing 3.48% and 2.09% of the respective share classes, and 2.06% and 0.85% of the total shares[95] - Zhou Yan

Financial Performance - Total revenue for the year ended December 31, 2022, was RMB 1,264,073 thousand, a decrease of 19.5% compared to RMB 1,570,129 thousand in 2021[2] - Gross profit for the same period was RMB 1,027,659 thousand, down 20.6% from RMB 1,294,700 thousand in the previous year[2] - Loss attributable to equity holders of the parent company was RMB 319,601 thousand, a 53.9% improvement from a loss of RMB 692,774 thousand in 2021[2] - The company reported a net loss of RMB 230,630 thousand for the year, compared to a net loss of RMB 675,873 thousand in 2021[4] - The group reported a pre-tax loss of RMB 434,165,000 for 2022, compared to a loss of RMB 606,703,000 in 2021, reflecting a reduction in losses[27] - The effective tax rate for the group was impacted by various factors, resulting in an income tax expense of RMB (203,535,000) for 2022, compared to RMB 69,170,000 in 2021[26] - The company did not recommend any dividends for the year ended December 31, 2022, consistent with the previous year[28] - The company's loss for 2022 was RMB 2,306 million, a reduction of RMB 4,452 million or 65.9% compared to a loss of RMB 6,759 million in 2021, mainly due to a significant decrease in share-based compensation expenses[71] Assets and Liabilities - Non-current assets increased to RMB 6,327,083 thousand as of December 31, 2022, from RMB 5,713,669 thousand in 2021[5] - Current assets totaled RMB 2,548,703 thousand, up from RMB 2,358,684 thousand in the previous year[5] - Current liabilities rose to RMB 2,249,797 thousand, compared to RMB 1,570,042 thousand in 2021[6] - The company's total assets minus current liabilities stood at RMB 6,625,989 thousand, slightly up from RMB 6,502,311 thousand in 2021[6] - The company's total financial liabilities as of December 31, 2022, amounted to RMB 13,987 million, an increase of RMB 7,482 million or 115% from RMB 6,504 million at the end of 2021, mainly due to increased bank borrowings for industrialization and working capital[76] - The company's current ratio as of December 31, 2022, was approximately 1.13, with current assets of RMB 25,487 million and current liabilities of RMB 22,498 million[72] Revenue Sources - The revenue from vaccine sales was RMB 1,264,038 thousand, while R&D services contributed RMB 2,847 thousand[18] - The company operates a single business segment focused on vaccine sales and R&D services, with all revenues generated in China[16][17] - Sales of the freeze-dried human rabies vaccine (Vero cells) accounted for 61.5% of total revenue in 2022, while the recombinant hepatitis B vaccine (Hanssen yeast) accounted for 34.6%[36] - As of December 31, 2022, 34.6% of the company's revenue came from hepatitis B vaccine sales, while 61.5% came from rabies vaccine sales[38][39] Research and Development - The company plans to continue its focus on research and development of human vaccines, with ongoing projects in various subsidiaries[7] - Research and development expenses increased by 62.8% to RMB 500.3 million in 2022, up from RMB 307.4 million in 2021, due to advancements in vaccine development[64] - The company has 22 vaccine candidates in its pipeline targeting 14 disease areas, with nine products having obtained 13 clinical approvals[37] - The company is developing a mRNA vaccine for respiratory syncytial virus (RSV), with plans to submit a clinical trial application in Q2 2024[44] - The company has a robust internal R&D team responsible for all stages of vaccine development, including preclinical research, laboratory studies, clinical trials, regulatory filings, and manufacturing process development[51] Production and Operations - The company operates four licensed factories and has five validated human vaccine platform technologies[35] - As of December 31, 2022, the company has passed all GMP inspections for its four licensed factories, which have a combined production capacity of 91.3 million doses annually[52][53] - The company plans to establish new production facilities in the coming years to meet the strong demand for its existing vaccine products, with several new production workshops already completed and in the validation phase[54] - The company has resumed production of the hemorrhagic fever vaccine after relocating to a new production line that passed GMP inspection in June 2022[42] Market and Strategic Outlook - The Chinese vaccine market is projected to grow from RMB 761 billion in 2021 to RMB 2,157 billion by 2030, significantly outpacing the global market growth[56] - The company is focusing on innovative vaccine development, including mRNA and recombinant vaccines, which have gained momentum due to the COVID-19 pandemic[56] - The company plans to enhance its specialized sales promotion network to support product promotion and market penetration in 2023[58] - The company is actively optimizing production plans and improving automation processes to ensure stable and high-quality supply across its licensed factories[54] Employee and Governance - As of December 31, 2022, the company had approximately 1,576 employees, an increase from about 1,469 employees as of December 31, 2021[83] - Total employee benefits expenses for the year 2022 amounted to RMB 608.0 million, down from RMB 1,311.6 million in 2021[83] - The audit committee has been established in accordance with listing rules and includes five members, ensuring proper governance[88] Financing and Investments - The company's financing costs for 2022 amounted to RMB 257 million, an increase of RMB 150 million or 140.1% compared to RMB 107 million in 2021, primarily due to rising bank loan interest[68] - The net proceeds from the initial public offering (IPO) were approximately HKD 91.61 million, which have not been utilized as of December 31, 2022[85] - The company plans to allocate HKD 38,747,000 (42.30%) of the net proceeds for clinical trials of its mRNA COVID-19 vaccine, expected to be completed by June 2024[86] - An additional HKD 32,060,000 (35.00%) is earmarked for the construction of new production facilities for vaccine products, with completion expected by December 2023[86]